In vivo 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy

NMR in Biomedicine

Volumn 9, Issue 8, 1996, Pages 347-358

  Möller, Harald E ^a   Vermathen, Peter ^a,e   Rummeny, Ernst ^a   Wörtler, Klaus ^a   Wuisman, Paulus ^b   Rössner, Albert ^c   Wörmann, Bernhard ^d   Ritter, Jörg ^a   Peters, Peter E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; in vivo 31P NMR spectroscopy; Treatment response

Indexed keywords

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND; PENTETIC ACID; PHOSPHORUS;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; BONE TUMOR; CHILD; FEMALE; HUMAN; MALE; MIDDLE AGED; MUSCLE TUMOR; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; FEMALE; GADOLINIUM; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; PHOSPHORUS; SOFT TISSUE NEOPLASMS;

EID: 0030299081     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-1492(199612)9:8<347::aid-nbm431>3.0.co;2-3     Document Type: Article

References (50)

1. Glasser, D. B., Lane, J. M., Huvos, A. G., Marcove, R. C. and Rosen, G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 69, 698-708 (1992).
2. Springfield, D. S. Introduction to limb-salvage surgery for sarcomas. Orthop. Clin. N. Am. 22, 1-5 (1991).
3. McDonald, D. J. Limb-salvage surgery for treatment of sarcomas of the extremities. Am. J. Roentgenol. 163, 514-516 (1994).
4. Huvos, A. G., Rosen, G. and Marcove, R. C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch. Pathol. Lab. Med. 101, 14-18 (1977).
5. Salzer-Kuntschik, M., Delling, D., Beron, G. and Sigmund, R. Morphologic grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J. Cancer Res. Clin. Oncol. 106 Suppl., 21-24 (1983).
6. Winkler, K., Bielack, S. S., Delling, G., Jürgens, W., Kotz, R. and Salzer-Kuntschik, M. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat. Res. 62, 269-277 (1993).
7. Jürgens, W., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voute, T., Winkelmann, W., Winkler, K. and Göbel, U. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer 61, 23-32 (1988).
8. 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res. 49, 4075-4085 (1989).
9. Negendank, W. Studies of human tumors by MRS: a review. NMR Biomed. 5, 303-324 (1992).
10. 31P MRS of experimental tumors. NMR Biomed. 6, 345-356 (1993).
11. Leach, M. O. magnetic resonance spectroscopy applied to clinical oncology. Technol. Health Care 2, 235-246 (1994).
12. 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy. Magn. Reson. Med. 16, 19-34 (1990).
13. Sostman, H. D., Prescott, D. M., Dewhirst, M. W., Dodge, R. K., Thrall, D. E., Page, R. L. Tucker, J. A., Harrelson, J. M., Reece, G., Leopold, K. A., Oleson, J. R. and Charles, H. C. MR imaging and spectroscopy for prognostic evaluation in softtissue sarcomas. Radiology 190, 269-275 (1994).
14. Ross, B., Helsper, J. T., Cox, J., Young, I. R., Kempf, R., Makepeace, A. and Pennock, J. Osteosarcoma and other neoplasms of bone. Arch. Surg. 122, 1464-1469 (1987).
15. Semmler, W., Gademann, G., Bachert-Baumann, P., Zabel, H. J., Lorenz, W. and van Kaick, G. Monitoring human tumor response to therapy by means of P-31 MR spectroscopy. Radiology 166, 533-539 (1988).
16. Bryant, D. J., Bydder, G. M., Case, H. A., Collins, A. G., Cox, I. J., Makepeace, A. and Pennock, J. M. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in non-Hodgkin's lymphoma. J. Comput. Assist. Tomogr. 12, 770-774 (1988).
17. Karczmar, G. S., Meyerhoff, D. J., Boska, M. D., Hubesch, B., Poole, J., Matson, G. B., Valone, F. and Weiner, M. W. P-31 spectroscopy study of response of superficial human tumors to therapy. Radiology 179, 149-153 (1991).
18. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn. Reson. Med. 25, 30-44 (1992).
19. 31P-NMR-Spektroskopie des Muskels. Ph.D. thesis, Universität Münster (1991).
20. 31P NMR spectroscopy by combining surface coils and slice-selective saturation. J. Magn. Reson. 75, 167-173 (1987).
21. Brown, T. R., Kincaid, B. M. and Ugurbil, K. NMR chemical shift imaging in three dimensions. Proc. Natl. Acad. Sci. USA 79, 3523-3526 (1982).
22. Sostman, H. D., Charles, H. C., Rockwell, S., Leopold, K., Beam, C., Madwed, D., Dewhirst, M., Cofer, G., Moore, D., Burn, R. and Oleson, J. Soft-tissue sarcomas: detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 176, 837-843 (1990).
23. Taylor, D. J., Styles, P., Matthews, P. M., Arnold, D. H., Gadian, D. G., Bore, P. and Radda, G. K. Energetics of human calf muscle: exercise-induced ATP depletion. Magn. Reson. Med. 3, 44-54 (1986).
24. 31P NMR chemical shifts of ATP. Anal. Biochem. 214, 458-467 (1993).
25. Lenkinski, R. E., Listerud, J., Shinkwin, M. A., Zlatkin, M. B., Kressel, H. Y., Schmidt, R. G. and Daly, J. M. Magnetic resonance imaging and magnetic resonance spectroscopy of bone tumors and bone marrow disease. Invest. Radiol. 24, 1006-1010 (1989).
26. Zlatkin, M. B., Lenkinski, R. E., Shinkwin, M., Schmidt, R. G., Daly, J. M., Holland, G. A., Frank, T. and Kressel, H. Y. Combined MR imaging and spectroscopy of bone and soft tissue tumors. J. Comput. Assist. Tomogr. 14, 1-10 (1990).
27. 31P spectroscopy. NMR Biomed. 2, 284-289 (1989).
28. 31P MRS in vivo. Part II: muscle, liver, kidney. Magn. Reson. Med. 32, 453-458 (1994).
29. 2 relaxation times in rat brain and in rat brain tumors implanted to nude mouse. Magn. Reson. Med. 4, 144-152 (1987).
30. 31P-labeled topical magnetic resonance spectroscopy to monitor in vivo tumor metabolism in rats. Cancer Res. 45, 481-486 (1985).
31. 31P MRS: correlation of longitudinal relaxation with tumor growth rate and DNA synthesis. Int. J. Radiat. Oncol. Biol. Phys. 14, 1185-1195 (1988).
32. 31P magnetic resonance spectroscopy. Magn. Reson. Med. 23, 302-310 (1992).
33. 31P-magnetic resonance spectroscopy in vivo of four human melanoma xenograft lines: spin-lattice relaxation times. Radiother. Oncol. 32, 54-62 (1994).
34. Cady, E. B. and Azzopardi, D. Absolute quantitation of neonatal brain spectra acquired with surface coli localization. NMR Biomed 2, 305-311 (1989).
35. Negendank, W. G., Crowley, M. G., Ryan, J. R., Keller, N. A. and Evelhoch, J. L. Bone and soft-tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy. Radiology 173, 181-188 (1989).
36. Shinkwin, M. A., Lenkinski, R. E., Daly, J. M., Zlatkin, M. B., Frank, T. S., Holland, G. A. and Kressel, H. Y Integrated magnetic resonance imaging and phosphorus spectroscopy of soft tissue tumors. Cancer 67, 1849-1858 (1991).
37. Negendank, W. G., Padavic-Shaller, K. A., Li, C. W., Murphy-Boesch, J., Stoyanova, R., Krigel, R. L., Schilder, R. J., Smith, M. R. and Brown, T. R. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of protondecoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 55, 3286-3294 (1995).
38. Tannock, I. F. and Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49, 4373-4384 (1989).
39. 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res. 47, 3396-3401 (1987).
40. 31P MRS observations of tumor energy metabolism. NMR Biomed. 5, 279-289 (1992).
41. Vaupel, P., Kallinowski, F. and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 43, 6449-6465 (1989).
42. Griffiths, J. R. Are cancer cells acidic? Br. J. Cancer 64, 425-427 (1991).
43. Masuda, T., Dobson, G. P. and Veech, R. The Gibbs-Donnan near-equilibrium system of heart. J. Biol. Chem. 265, 20,321-20,334 (1990).
44. Stubbs, M., Rodrigues, L., Howe, F. A., Wang, J., Jeong, K. S., Veech, R. L. and Griffiths, J. R. Metabolic consequences of a reversal pH gradient in rat tumors. Cancer Res. 54, 4011-4016 (1994).
45. Ebel, H. and Günther, T. Magnesium metabolism: a review. J. Clin. Chem. Clin. Biochem. 18, 257-270 (1980).
46. Ruiz-Cabello, J. and Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5, 226-223 (1992).
47. 31P NMR spectroscopy of in vivo tumors. J. Magn. Reson. 49, 271-286 (1982).
48. 31P NMR for non-invasive evaluation of tumor metabolic status. Int. J. Radiat. Oncol. Biol. Phys. 12, 793-799 (1986).
49. 31P magnetic resonance spectroscopy. Adv. Enzyme Regul. 30, 217-230 (1990).
50. Chabner, B. A. The oncologic end game. J. Clin. Oncol. 4, 625-638 (1986).